Trevena (NASDAQ:TRVN) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Trading Down 9.5 %

Shares of NASDAQ TRVN opened at $1.99 on Friday. The company has a market capitalization of $36.50 million, a price-to-earnings ratio of -0.74 and a beta of 1.02. Trevena has a twelve month low of $1.13 and a twelve month high of $19.23. The business has a 50 day simple moving average of $3.77 and a 200-day simple moving average of $6.46.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($9.25) by $9.02. The business had revenue of $0.33 million for the quarter. As a group, equities analysts predict that Trevena will post -32.25 earnings per share for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.